Publicaciones en colaboración con investigadores/as de Memorial Sloan Kettering Cancer Center (27)

2024

  1. Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

    Nature Medicine, Vol. 30, Núm. 1, pp. 271-278

2023

  1. Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer

    Journal of Hematology and Oncology, Vol. 16, Núm. 1

  2. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study

    The Lancet Oncology, Vol. 24, Núm. 8, pp. 925-935

  3. HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 35, pp. 5363-5375

  4. Inhibition of HSP90 in Driver Oncogene-Defined Lung Adenocarcinoma Cell Lines: Key Proteins Underpinning Therapeutic Efficacy

    International Journal of Molecular Sciences, Vol. 24, Núm. 18

  5. Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis

    Annals of Oncology, Vol. 34, Núm. 2, pp. 173-185

  6. Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.

    New England Journal of Medicine, Vol. 389, Núm. 8, pp. 710-721

  7. Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 2893-2903

  8. Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B

    Cell Reports Medicine, Vol. 4, Núm. 11

2022

  1. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer

    Annals of Oncology, Vol. 33, Núm. 5, pp. 466-487

  2. First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

    Journal of Thoracic Oncology, Vol. 17, Núm. 2, pp. 289-308

  3. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 12, pp. 1301-1311

  4. LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive non-small-cell lung cancer

    Future oncology (London, England), Vol. 18, Núm. 28, pp. 3133-3141

  5. Trastuzumab deruxtecan in HER2-mutant non–small-cell lung cancer

    New England Journal of Medicine, Vol. 386, Núm. 3, pp. 241-251

2021

  1. Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial

    Journal of Thoracic Oncology, Vol. 16, Núm. 5, pp. 860-867

  2. Identification of predictive biomarkers of response to hsp90 inhibitors in lung adenocarcinoma

    International Journal of Molecular Sciences, Vol. 22, Núm. 5, pp. 1-18

  3. Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours

    ESMO open, Vol. 6, Núm. 3, pp. 100113

  4. Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics

    European Journal of Cancer, Vol. 151, pp. 211-220

2020

  1. IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy

    Journal of Thoracic Oncology, Vol. 15, Núm. 5, pp. 709-740

2019

  1. Combined PIK3CA and FGFR inhibition with alpelisib and infigratinib in patients with PIK3CA-mutant solid tumors, with or without fgfr alterations

    JCO Precision Oncology